Stock comparison
Genmab A/S
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 69B | MTD |
| Benjamin Graham | 64C | 65B | MTD |
| Philip Fisher | 48D | 63C | MTD |
| Peter Lynch | 25F | 66B | MTD |
| Joel Greenblatt | 76B | 68B | GMAB |
| Charlie Munger | 68C | 74B | MTD |
| Terry Smith | 71C | 70B | GMAB |
Side-by-side metrics
| Metric | GMAB | MTD |
|---|---|---|
| Market cap | $16.5B | $22.29B |
| P/E (TTM) | 6.2x | 25.3x |
| EV/EBIT | 12.0x | 21.6x |
| ROIC (TTM) | 43.78% | 36.09% |
| Gross margin | 93.88% | 57.79% |
| Net margin | 18.23% | 21.4% |
| Revenue CAGR 5y | -18.45% | 2.01% |
| EPS CAGR 5y | -23.48% | 6.12% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- P/E (TTM)6.2xvs 25.3x+76%
- EV/EBIT12.0xvs 21.6x+45%
- Gross margin93.88%vs 57.79%+38%
- ROIC (TTM)43.78%vs 36.09%+18%
MTD leads on
- EPS CAGR 5y6.12%vs -23.48%+126%
- Revenue CAGR 5y2.01%vs -18.45%+111%
- Debt / Equity-vs 0.1x+100%
- Market cap$22.29Bvs $16.5B+26%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.